This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

IDDM (type 1 diabetes)

Authoring team

Type 1 diabetes mellitus (T1D) or previously known as insulin dependent diabetes (IDDM), is a condition characterised by persistent hyperglycaemia due to absolute insulin deficiency caused by autoimmune destruction of the insulin-producing beta cells of the pancreas (1).

Nearly 90% of T1D patients have one or more islet autoantibodies such as insulin (IAA), glutamic acid decarboxylase (GADA), insulinoma-associated autoantigen 2 (IA-2), and zinc transporter 8 (ZnT8A) (2)

  • studies of first-degree relatives of patients with T1D have reported that the persistent presence of two or more autoantibodies is an almost certain predictor of clinical hyperglycemia and diabetes.
    • the rate of progression is dependent on the age at first detection of antibody, number of antibodies, antibody specificity, and antibody titer (3)
  • in some parts of the world (in Africa and Asia), a significant proportion of patients are negative for autoantibodies and this type of T1D is termed “idiopathic” (type 1b) (1)

Historically, T1D was considered as a disorder in children and adolescents. However this opinion has changed over the past decade and people with T1D may present at any age (2)

  • differential diagnosis of diabetes in children, adolescents and young adults has become a challenging task due to the emergence of type 2 diabetes mellitus (T2D), and the increasing prevalence of obesity in the general population, which minimizes the value of body mass index as a distinguishing feature between T1D and T2D (3).

The Juvenile Diabetes Research Foundation, American Diabetes Association and the Endocrine Society have identified three stages of “early” T1D:

  • stage 1 - individual has evidence of autoimmunity but is normoglycemic
  • stage 2 - there is evidence of glucose intolerance
  • stage 3 - characterized by symptomatic hyperglycemia

Note: “Pre-Stage 1” has also been described which includes individuals with a genetic predisposition to islet-cell autoimmunity in whom autoantibodies are as yet undetectable (1).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.